The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes

Simple item page
dc.contributor.authorZomer, E.
dc.contributor.authorZhou, J.
dc.contributor.authorNelson, A.J.
dc.contributor.authorSumithran, P.
dc.contributor.authorNanayakkara, S.
dc.contributor.authorBall, J.
dc.contributor.authorKaye, D.
dc.contributor.authorLiew, D.
dc.contributor.authorNicholls, S.J.
dc.contributor.authorStub, D.
dc.contributor.authorZoungas, S.
dc.date.issued2024
dc.descriptionPublished online 02 August 2024; OnlinePubl
dc.description.abstractBackground and aims The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated significant reductions in cardiovascular outcomes in people with cardiovascular disease (CVD) and overweight or obesity (but without diabetes). However, the cost of the medication has raised concerns about its financial viability and accessibility within healthcare systems. This study explored whether the use of semaglutide for the secondary prevention of CVD in overweight or obesity is cost-effective from the Australian healthcare perspective. Methods and results A Markov model was developed based on the SELECT trial to model the clinical outcomes and costs of a hypothetical population treated with semaglutide vs. placebo, in addition to standard care, and followed up over 20 years. With each annual cycle, subjects were at risk of having non-fatal CVD events or dying. Model inputs were derived from SELECT and published literature. Costs were obtained from Australian sources. All outcomes were discounted by 5% annually. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. With an annual estimated cost of semaglutide of A$4175, the model resulted in ICERs of A$99 853 (US$143 504; £40 873) per YoLS and A$96 055 (US$138 046; £39 318) per QALY gained. Conclusion Assuming a willingness-to-pay threshold of A$50 000, semaglutide is not considered cost-effective at the current price. A price of ≤A$2000 per year or more targeted use in high-risk patients would be needed for it to be considered cost-effective in the Australian setting.
dc.description.statementofresponsibilityElla Zomer, Jennifer Zhou, Adam J. Nelson, Priya Sumithran, Sha ne Na naya kka ra, Joc ast a Ba ll, David Kaye, Danny Liew, Stephen J. Nicholls, Dion Stub, and Sophia Zoungas
dc.identifier.citationEuropean Heart Journal - Quality of Care and Clinical Outcomes, 2024; qcae063-1-qcae063-11
dc.identifier.doi10.1093/ehjqcco/qcae063
dc.identifier.issn2058-5225
dc.identifier.issn2058-1742
dc.identifier.orcidNelson, A.J. [0000-0003-0990-2548]
dc.identifier.orcidLiew, D. [0000-0002-0131-623X] [0000-0003-2064-181X]
dc.identifier.urihttps://hdl.handle.net/2440/143584
dc.language.isoen
dc.publisherOxford University Press
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/2030768
dc.rights© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
dc.source.urihttp://dx.doi.org/10.1093/ehjqcco/qcae063
dc.subjectCardiovascular disease
dc.subjectGLP-1RAs, cost-effectiveness
dc.subjectObesity
dc.subjectSemaglutide
dc.titleThe cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Research Outputs